SRI to 13 - continuous rodent and non-rodent pharmacokinetic assessments
Ended Awarded Last action
- Contract number
- 75N95022F00001
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,534,575
Award facts
- Contract value 35% obligated
-
- $2,534,574.93 Current, with exercised options
- $7,323,160.93 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $392,847 | |
| Funding Only Action | -$552,508 | |
| Exercise an Option | $392,847 | |
| Exercise an Option | $770,545 | |
| Exercise an Option | $385,272 | |
| Exercise an Option | $385,272 | |
| Exercise an Option | $380,150 | |
| Original award | $380,150 |
About this award
This is a $7,323,160.93 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the Department of Health and Human Services (HHS). The contract is for continuous rodent and non-rodent pharmacokinetic assessments under the Pharmacology and Toxicology for Therapeutics Program (PTTP) IDIQ contract. The prime contractor is SRI International, a large non-profit research and development institute that frequently partners with federal agencies on biomedical research, engineering, and technical services contracts and grants. There is no set-aside designation for this award, which runs through March 16, 2027. As a PTTP IDIQ task order, this contract allows NINDS to efficiently procure SRI's specialized expertise in preclinical drug development and testing services.
Quick answers
Who was awarded contract 75N95022F00001?
75N95022F00001 was awarded to Sri International by National Institute on Drug Abuse (National Institutes of Health) on March 14, 2022.
How much is contract 75N95022F00001 worth?
The government has obligated $2,534,575 on 75N95022F00001. Its potential value, with all options, is $7,323,161.
Which agency awarded contract 75N95022F00001?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022F00001, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95022F00001 an order under another contract?
Yes. 75N95022F00001 is a delivery order under HHSN271201600006I, an indefinite delivery contract, on Pharmacology and Toxicology for Therapeutics Program (PTTP).
Was contract 75N95022F00001 competed?
The extent of competition for 75N95022F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award